HPV-mediated inactivation of tumor suppressor p53.
作者信息
Travé Gilles, Zanier Katia
机构信息
a Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR 7104, Université de Strasbourg , Illkirch , France.
b Biotechnologie et Signalisation Cellulaire (UMR 7242), Ecole Superieure de Biotechnologie de Strasbourg , Illkirch , France.
出版信息
Cell Cycle. 2016 Sep;15(17):2231-2. doi: 10.1080/15384101.2016.1191257. Epub 2016 May 31.
Abstract
摘要
相似文献
1
HPV-mediated inactivation of tumor suppressor p53.
Cell Cycle. 2016 Sep;15(17):2231-2. doi: 10.1080/15384101.2016.1191257. Epub 2016 May 31.
2
Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Virology. 2002 Jul 20;299(1):72-87. doi: 10.1006/viro.2002.1502.
3
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53.
Cell. 1990 Dec 21;63(6):1129-36. doi: 10.1016/0092-8674(90)90409-8.
4
Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
Cell. 1991 Nov 1;67(3):547-56. doi: 10.1016/0092-8674(91)90529-8.
5
Comparison of human papillomavirus type 18 (HPV-18) E6-mediated degradation of p53 in vitro and in vivo reveals significant differences based on p53 structure and cell type but little difference with respect to mutants of HPV-18 E6.
J Gen Virol. 1998 Aug;79 ( Pt 8):1963-70. doi: 10.1099/0022-1317-79-8-1963.
6
Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
Cancer Surv. 1992;12:197-217.
7
8
Interference of proteins involved in the cytoplasmic sequestration of p53 with human papillomavirus E6-mediated degradation.
Mol Carcinog. 1999 Jan;24(1):70-7. doi: 10.1002/(sici)1098-2744(199901)24:1<70::aid-mc10>3.0.co;2-5.
9
Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
Oncogene. 1997 Jul 17;15(3):257-64. doi: 10.1038/sj.onc.1201202.
10
Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
FEBS Lett. 2003 Feb 11;536(1-3):220-4. doi: 10.1016/s0014-5793(03)00054-1.
引用本文的文献
1
Transforming Properties of E6/E7 Oncogenes from Beta-2 HPV80 in Primary Human Fibroblasts.
Int J Mol Sci. 2025 Jun 2;26(11):5347. doi: 10.3390/ijms26115347.
2
Oral Treatment with EGCG, Folic Acid, Vitamin B12, and Hyaluronic Acid Improves HPV Clearance and Counteracts Its Persistence: A Clinical Study.
Int J Mol Sci. 2025 May 29;26(11):5251. doi: 10.3390/ijms26115251.
3
The viral landscape in metastatic solid cancers.
Heliyon. 2025 Feb 8;11(4):e42548. doi: 10.1016/j.heliyon.2025.e42548. eCollection 2025 Feb 28.
4
Unraveling HPV-associated cancer complexity: From molecular insights to innovative therapies.
Heliyon. 2025 Feb 3;11(3):e42437. doi: 10.1016/j.heliyon.2025.e42437. eCollection 2025 Feb 15.
5
Treatment with Epigallocatechin Gallate, Folic Acid, Vitamin B12, and Hyaluronic Acid Decreases HPV Positivity in Women Attending Regional Screening in Puglia.
Microorganisms. 2024 Sep 14;12(9):1897. doi: 10.3390/microorganisms12091897.
6
Mutation-Mediated Immune Evasion in Cancer: Mechanisms and Therapeutic Implications.
Cancers (Basel). 2024 Sep 3;16(17):3069. doi: 10.3390/cancers16173069.
7
Counteracting HPV Cervical and Anal Infection through Dietary Supplementation of EGCG, Folic Acid, Vitamin B12 and Hyaluronic Acid: Clinical Case Reports.
J Clin Med. 2024 Jun 19;13(12):3597. doi: 10.3390/jcm13123597.
8
Human Oncogenic Viruses: Characteristics and Prevention Strategies-Lessons Learned from Human Papillomaviruses.
Viruses. 2024 Mar 8;16(3):416. doi: 10.3390/v16030416.
9
Comparative Analysis of Alpha and Beta HPV E6 Oncoproteins: Insights into Functional Distinctions and Divergent Mechanisms of Pathogenesis.
Viruses. 2023 Nov 14;15(11):2253. doi: 10.3390/v15112253.
10
BK polyomavirus: latency, reactivation, diseases and tumorigenesis.
Front Cell Infect Microbiol. 2023 Sep 13;13:1263983. doi: 10.3389/fcimb.2023.1263983. eCollection 2023.
本文引用的文献
1
Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Nature. 2016 Jan 28;529(7587):541-5. doi: 10.1038/nature16481. Epub 2016 Jan 20.
2
Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides.
PLoS One. 2015 Jul 7;10(7):e0132339. doi: 10.1371/journal.pone.0132339. eCollection 2015.
3
Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.
Science. 2013 Feb 8;339(6120):694-8. doi: 10.1126/science.1229934.
4
Peptide interactions stabilize and restructure human papillomavirus type 16 E6 to interact with p53.
J Virol. 2012 Oct;86(20):11386-91. doi: 10.1128/JVI.01236-12. Epub 2012 Aug 15.
5
Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.
Structure. 2012 Apr 4;20(4):604-17. doi: 10.1016/j.str.2012.02.001. Epub 2012 Apr 3.
6
The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53.
Virology. 2009 Feb 20;384(2):285-93. doi: 10.1016/j.virol.2008.09.034. Epub 2008 Dec 11.
7
Association of human papillomavirus types 16 and 18 E6 proteins with p53.
Science. 1990 Apr 6;248(4951):76-9. doi: 10.1126/science.2157286.
Zotero 插件